In this issue of the magazine, we talk all things ACMG, and speak to some of the most prolific figures in the industry.
AstraZeneca has made the decision to push six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases.
New research shows that a test for measuring the length of DNA endcaps called telomeres can alter treatment decisions for patients with certain types of bone marrow failures.
“How Can We Anticipate and Respond to Technologies and Information That is Rapidly Changing?” – Josephine Johnston
Josephine Johnston is an expert on the ethical, legal and policy implications of biomedical technologies, particularly as used in human reproduction, psychiatry, genetics, and neuroscience.
U.S. drugmaker Gilead Sciences has announced that it will use Sangamo Therapeutics gene-editing technology to develop cancer treatments in a deal worth potentially $3 billion to Sangamo.
Scientists at the UNC School of Medicine and NC State have created an injectable gel-like scaffold that can hold combination chemo-immunotherapeutic drugs and deliver them locally to tumours in a sequential manner.